Reported Saturday, Arvinas Reports ARV-393 Plus Glofitamab Delivers Significantly Enhanced Tumor Growth Inhibition And Increased Tumor Regression Versus Either Agent Alone

Benzinga · 2d ago

Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026